| Autor: |
Imahayashi, Satoru, Yoshino, Ichiro, Eifuku, Ryozo, Takenoyama, Mitsuhiro, Hanagiri, Takeshi, Yasumoto, Kosei |
| Zdroj: |
Japanese Journal of Thoracic & Cardiovascular Surgery; 2000, Vol. 48 Issue 3, p166-172, 7p |
| Abstrakt: |
Objective: We studied the ability of human lung-cancer-specific cytotoxic T lymhocytes to suppress the growth of human lung adenocarcinoma (PC-9) engrafted in severe combined immunodeficiency mice. Methods: PC-9-specific cytotoxic T lymhocytes were generated by multiple stimulation with irradiated PC-9 cells of regional lymph node lymphocytes from lung cancer patients expressing the same human leukocyte antigen-A locus haplotype as PC-9 following expansion due to the administration of immobilized anti cluster of differentiation 3 mAb and interleukin-2. Cytotoxic T lymhocytes showed specific cytotoxicity against PC-9 cells in vitro. Severe combined immunodeficiency mice with a subcutaneous graft of PC-9 were treated with a PC-9-specific cytotoxic T lymhocyte by i.V. injection and/or with interleukin-2 by s.c. injection. Results: Cytotoxic T lymhocyte treatment suppressed PC-9 graft growth significantly an effect, significantly enhanced when combined with interleukin-2 injection. To evaluate the in vivo specificity of anti-PC-9 cytotoxic T lymhocytes, each mouse was subcutaneously inoculated in the right flank with PC-9, and in the left flank with A549 or Sq-1. Cytotoxic T lymhocytes plus interleukin-2 treatment was found to suppress PC-9 growth selectivly, but not A549 or Sq-1 growth. Conclusions: These results provide sufficient rationale for conducting further clinical trials on immunotherapy using cytotoxic T lymhocyte for lung cancer patients. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink